Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Aura Biosciences Inc
(NQ:
AURA
)
7.350
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aura Biosciences Inc
< Previous
1
2
3
4
Next >
Aura Biosciences Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
August 11, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences to Participate at the 2022 BTIG Biotechnology Conference
August 02, 2022
From
Aura Biosciences, Inc.
Via
Business Wire
JMP Is Bullish On This Cancer Stock "Sees New Way to Treat Cancer"
July 19, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 19, 2022
July 19, 2022
Upgrades
Via
Benzinga
Aura Biosciences' Belzupacap Sarotalocan At Par With Plaque Radiotherapy In Eye Cancer
June 23, 2022
Via
Benzinga
Aura Biosciences' Stock Gains As FDA Grants Fast Track Status To Bladder Cancer Drug
June 30, 2022
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Aura Biosciences’ (NASDAQ: AURA) belzupacap sarotalocan (AU-011) for the treatment of Non-Muscle Invasive Bladder...
Via
Benzinga
The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial
June 30, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
June 30, 2022
From
Aura Biosciences, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
June 22, 2022
Gainers ABVC BioPharma (NASDAQ:ABVC) shares increased by 12.3% to $1.03 during Wednesday's after-market session. The company's market cap stands at $33.2 million.
Via
Benzinga
Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma
June 22, 2022
From
Aura Biosciences Inc.
Via
Business Wire
The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial
June 21, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Aura Biosciences to Present Updated Belzupacap Sarotalocan (AU-011) Data on Multiple Studies at the International Society of Ocular Oncology 2022 Bi-Annual Meeting
June 17, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting
May 26, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences to Participate in Upcoming Investor Conferences
May 25, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
May 12, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences Presents Preclinical Data Highlighting AU-011’s Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting
May 03, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences to Present at the 2022 Bank of America Healthcare Conference
May 03, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights
March 23, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences Announces Orphan Drug Designation Granted to AU-011 by European Commission for the Treatment of Uveal Melanoma (Includes Choroidal Melanoma)
March 21, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences to Host Virtual Investor Day Focused on Ocular Oncology with Key Thought Leaders on March 22
March 15, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences to Participate at the 42nd Annual Cowen Virtual Health Care Conference
February 28, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences to Present Preclinical Data Demonstrating Applicability of AU-011 in Bladder Cancer at the 2022 ASCO Genitourinary Cancer Symposium
February 14, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare Conference
February 09, 2022
From
Aura Biosciences, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
November 29, 2021
Gainers Krystal Biotech (NASDAQ:KRYS) shares moved upwards by 118.21% to $86.87 during Monday's regular session. Krystal Biotech's stock is trading at a volume of...
Via
Benzinga
52 Biggest Movers From Yesterday
January 20, 2022
Gainers Zogenix, Inc. (NASDAQ: ZGNX) shares surged 65.7% to close at $25.92 on Wednesday after the company announced it will be acquired by UCB for approximately $1.9 billion. G...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
November 24, 2021
Gainers iSpecimen (NASDAQ:ISPC) shares in...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
November 24, 2021
Gainers Biofrontera (NASDAQ:BFRI) shares ...
Via
Benzinga
50 Biggest Movers From Yesterday
November 30, 2021
Gainers Krystal Biotech, Inc. (NASDAQ: KRYS) shares surged 121.7% to close at $88.24 on Monday after the company announced positive topline results from the GEM-3 Phase 3 trial...
Via
Benzinga
Aura Biosciences to Participate at the 4th Annual Evercore ISI HealthCONx Conference
November 23, 2021
From
Aura Biosciences, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 23, 2021
November 23, 2021
Upgrades Keefe, Bruyette & Woods upgraded the previous rating for CBRE Group Inc (NYSE:
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.